At Lonza Pharma & Biotech, we provide contract development and manufacturing services that enable pharma and biotech companies to bring medicines to patients in need. From the building blocks of life to the final drug product, our solutions are created to simplify your outsourcing experience and provide a reliable outcome when you expect it. Our extensive track record includes commercialization of pioneering therapies and manufacturing of a wide variety of biological and chemical drugs. We continuously invest to solve not just the current, but also the future challenges. Together, let’s bring your next medicine to life.
RoosterBio manufactures high-volume, well-characterized hMSCs paired with bioprocess media systems and reagents that radically simplify production of Extracellular Vesicles (EVs). Having a consistent, ready-supply of hMSC and EVs enables RoosterBio product users to leap ahead in research, product development, and manufacturing and enter clinical trials much faster and at much lower cost than older, slower, more expensive methods.
FUJIFILM Wako Pure Chemical Corporation is a world-renowned supplier of high purity laboratory chemicals for research and development. Our comprehensive product portfolio includes analytical reagents, fine chemicals and life science products. We focus on creating new value for our customers and are continuously engaged in developing new technologies. In Exosome Based Therapeutic Development, we introduce PS Affinity method for isolating and detecting extracellular vesicles. It enables easy isolation of high purity and high yield EVs.
Celonic Group is a privately-owned CDMO based in Basel, Switzerland, with a state-of-the-art bio manufacturing facility in Heidelberg, Germany. Celonic provides comprehensive development and manufacturing services for bio therapeutics including cell line development, USP and DSP development, GMP and non-GMP manufacturing of biopharmaceutical drug substances and drug products, along with cell expression platforms and diagnostics. Celonic offers two cell expression platforms to clients, developers, and service providers – CHOvolution®, developed by Celonic and GEX®, developed by Glycotope GmbH and in-license by Celonic. With a new GMP manufacturing facility for gene vectors and cell therapy, Celonic is soon expanding its services to the manufacturing of gene vectors and allogeneic cell batches